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Abstract
The availability of a highly purified and well characterized circumsporozoite protein (CSP) is essential to improve upon the
partial success of recombinant CSP-based malaria vaccine candidates. Soluble, near full-length, Plasmodium falciparum CSP
vaccine antigen (CS/D) was produced in E. coli under bio-production conditions that comply with current Good
Manufacturing Practices (cGMP). A mouse immunogenicity study was conducted using a stable oil-in-water emulsion (SE) of
CS/D in combination with the Toll-Like Receptor 4 (TLR4) agonist Glucopyranosyl Lipid A (GLA/SE), or one of two TLR7/8
agonists: R848 (un-conjugated) or 3M-051 (covalently conjugated). Compared to Alum and SE, GLA/SE induced higher CS/D
specific antibody response in Balb/c mice. Subclass analysis showed higher IgG2:IgG1 ratio of GLA/SE induced antibodies as
compared to Alum and SE. TLR synergy was not observed when soluble R848 was mixed with GLA/SE. Antibody response of
3M051 formulations in Balb/c was similar to GLA/SE, except for the higher IgG2:IgG1 ratio and a trend towards higher T cell
responses in 3M051 containing groups. However, no synergistic enhancement of antibody and T cell response was evident
when 3M051 conjugate was mixed with GLA/SE. In C57Bl/6 mice, CS/D adjuvanted with 3M051/SE or GLA/SE induced higher
CSP repeat specific titers compared to SE. While, 3M051 induced antibodies had high IgG2c:IgG1 ratio, GLA/SE promoted
high levels of both IgG1 and IgG2c. GLA/SE also induced more potent T-cell responses compared to SE in two independent
C57/BL6 vaccination studies, suggesting a balanced and productive TH1/TH2 response. GLA and 3M-051 similarly enhanced
the protective efficacy of CS/D against challenge with a transgenic P. berghei parasite and most importantly, high levels of
cytophilic IgG2 antibodies were associated with protection in this model. Our data indicated that the cGMP-grade, soluble
CS/D antigen combined with the TLR4-containing adjuvant GLA/SE warrants further evaluation for protective responses in
humans.
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Introduction
Malaria is a tropical disease that continues to cause wide spread
mortality and morbidity in some of the poorest regions in the
world. The development of a malaria vaccine could be a step
towards eradication of this intractable disease. The major coat
protein of Plasmodium sporozoites is the circumsporozoite protein
(CSP). RTS,S (Glaxosmithkline, GSK) is a recombinant form of
CSP that contains 18 NANP repeat units and the C-terminal
cysteine rich region of P. falciparum CSP fused to the hepatitis B
surface antigen and expressed in Saccharomyces yeast [1]. Early
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e111020
studies with an alum-adjuvanted RTS,S formulation showed only
limited protection in humans. This could be due to the fact that
alum induces primarily a TH2-type immune response [2,3] and
malaria infection is known to be at least partially controlled by
cellular immunity [4]. Additionally, the magnitude and avidity of
antibodies elicited by alum-based formulations may have been
insufficient to induce protection. Protection was enhanced in
humans when RTS,S was adjuvanted with the AS series of
adjuvants that contained the TH1 inducers monophosphoryl lipid
A or MPL (derived from bacterial cell wall lipopolysaccharide) and
QS21 (a compound fractionated from the Quillaja saponaria tree).
Vaccination with RTS,S+AS series adjuvants has since been
shown to reproducibly protect ,30–50% of vaccine recipients
[5,6] and protection has been associated with the induction of high
levels of CSP-specific antibodies and cytokine producing (IL-2+
and IFN-c+) CD4+ T cells [6,7].
A potent adaptive immune response requires prior engagement
of the innate immune system which can sense pathogen associated
molecular patterns using pattern recognition receptors. The toll-
like receptors (TLRs) are one of the best characterized families of
pattern recognition receptors present on macrophages and
dendritic cells [8]. In the mouse, TLRs 1, 2, 4, 5, 6 and 11 reside
on the cell surface and interact with surface ligands while TLRs 3,
7, 8 and 9 are located in endosomes where they recognize
pathogen nucleic acids [9]. Interaction of TLRs with their ligands
activates a signal cascade terminating at transcription factors NF-
kB and IRF-7 (MyD88 pathway) or IRF-3 (TRIF pathway) [10].
TLR signaling leads to the production of pro-inflammatory
cytokines, type-1 interferons and chemokines which promote
dendritic cell maturation and TH1 cell priming. TLR3 exclusively
utilizes the TRIF pathway for downstream signaling while all
other TLRs engage the MyD88 signal transduction cascade [11].
TLR4 is unique in its utilization of both the TRIF and MyD88
pathways [12]. Glucopyranosyl Lipid Adjuvant or GLA (Infectious
Disease Research Institute, IDRI) is a potent TLR4 agonist
(Fig. 1) and a homogenous synthetic analog of bacterial MPL [13].
Vaccines containing GLA have been tested clinically in nearly
1000 human subjects including those receiving pandemic flu
vaccines [14,15]. While MPL and GLA both promote robust TH1
responses, GLA has been reported to induce much stronger
dendritic cell (DC) and peripheral blood mononuclear cell (PBMC)
responses, and the addition of a stable oil-in-water emulsion (SE)
to GLA (GLA/SE) further enhances these responses [16].
Single-stranded, viral RNA present within DCs binds to the
TLR7 and TLR8 expressed on endosomal membranes [17]. Since
native RNA degrades rapidly in serum a family of synthetic
adjuvant compounds (imidazoquinolines) has been designed to
mimic single-stranded RNA [18]. Imiquimod (R-837) has been
used for topical immune therapy in millions of people in the
commercial ‘‘Aldara’’ cream for treatment of external genital
warts, basal cell carcinoma, and actinic keratosis. In addition,
Orthoro et al. recently reported that the topical application of
imiquimod at the site of subcutaneously injected Plasmodium
falciparum circumsporozoite peptides elicited strong parasite-
specific humoral immunity that protected against challenge with
transgenic rodent parasites that express P. falciparum CSP repeats
[19]. Structurally-similar TLR7/8 ligands such as resiquimod
(R848), 3M-012 and 3M-051 (3M Drug Delivery Systems) are also
under advanced consideration as vaccine adjuvants (Fig. 1) [20].
Elucidation of the molecular basis of antigen presentation is
allowing for the development of more potent adjuvant formula-
tions. Several groups are pursuing strategies that simultaneously
target multiple TLRs. Such approaches take advantage of the
differential location and signaling pathways used by various TLRs
and their prevalence on different sub-populations of DCs [21–26].
Leishmaniasis immunotherapy studies show that a combination of
MPL, a TRIF pathway-inducing TLR4 agonist, and CpG, a
MyD88-associated TLR9 adjuvant, can synergistically increase the
production of IL-12 and reduce the parasite burden in mice [27].
During an infection, TLR ligands and antigens are usually
structurally linked and enter into the same antigen presenting cell
[28]. Accordingly, another strategy of immune-enhancement is to
chemically couple the TLR agonist to the antigen to allow
simultaneous entry into the same DC. This approach leads to
more efficient MHC class II presentation and TH1 differentiation
[29]. Indeed, a covalent conjugate of HIV Gag protein with a
TLR7/8 agonist, 3M-012, was found to be more immunogenic
than a formulation containing unconjugated TLR7/8 agonist
[30]. While 3M-012 utilizes UV light activated phenylazide
chemistry for conjugation, its analog 3M-051 (used here) contains
a reactive nicotinate hydrazide group that binds to aromatic
aldehyde derivatized lysine residues on the antigen. Compared to
3M012, the 3M-051 coupling chemistry is more specific which
makes it easier to quantify the coupling efficiency and adjuvant
dose.
In an attempt to improve the protective efficacy of CSP-based
vaccines, a nearly full-length recombinant CSP (CS/D) was
produced in the Escherichia coli expression system under a GMP-
compliant environment. We then tested this recombinant protein
with adjuvant formulations containing the TLR agonists GLA,
R848 and 3M-051 (Fig. 1). The magnitude of antibody response,
subclass distribution, T cell response and protection against a
PfCSP-transgenic P. berghei parasite challenge were monitored.
The immunological outcome was highly dependent upon the
adjuvant used, and the degree of protection correlated with the
total IgG antibody titers as well as the level of induced cytophilic
Figure 1. Molecular structure of TLR agonists GLA, R848, and CS/D-3M051 conjugate.
doi:10.1371/journal.pone.0111020.g001
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Six- to eight-week old female Balb/c (H-2d) and C57Bl/6 (H-2b)
mice were purchased from the Jackson Laboratories (Bar Harbor,
ME). Animal procedures were conducted in compliance with the
Animal Welfare Act and other federal statutes and regulations
relating to animals and experiments involving animals and adhere
to principles stated in the Guide for the Care and Use of Laboratory
Animals, NRC Publication, 1996 edition. All procedures were
reviewed and approved by the Walter Reed Army Institute of
Research’s Animal Care and Use Committee (Protocol num-
ber:11-MVD-15), and performed in a facility accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care International.
CSP Vaccine Antigen Production
The 3D7-strain, P. falciparum CSP gene sequence (accession
No. XP_001351122.1) was used to express several CSP constructs
of varying repeat lengths (Fig. 2A). Based on the level of expression
and the ability to protect mice against parasite challenge, a
construct termed CS/D was chosen for process development. CS/
D contained 19 NANP and 3 NVDP repeats and the majority of
the N- and C-terminal regions of CSP (residues 26Tyr-127Asp
linked to 207Pro-383Ser). The gene used for expression was
optimized by changing 180 of the 278 native codons to
corresponding high abundance codons for E. coli. The AT
content of the optimized gene was reduced from 65% to 50%.
Expression cassettes were cloned in a pET32 plasmid (EMD
Millipore, Billerica, MA) modified to allow kanamycin-based
selection [31]. The CS/D-pET was transformed into the
SHUFFLE (DE3) E. coli strain (NEB, Ipswich, MA) for protein
expression.
Glycerol stocks of the CS/D-expressing clones were prepared in
plant based, phytone-containing medium. To initiate GMP
Figure 2. Recombinant CS/D constructs. A, Cartoon representation of the native P. falciparum CSP consisting of a signal sequence and GPI
anchor sequence (red), N-terminal region (green), NVDP and NANP repeats (blue) and a cysteine rich C-terminal region (purple). The expressed
constructs (CS/A, CS/C, CS/D and CS/E), their PfCSP-specific start and end residues, and the relative positions of the five cysteine residues (‘‘C’’) are
shown. B, SDS-PAGE shows relative expression levels (arrows) in un-induced (Un) and induced (In) E. coli cells producing CS/C, CS/D and CS/E.
doi:10.1371/journal.pone.0111020.g002
Table 1. Specifications of cGMP-grade CS/D product.
Characteristic Result Method
Protein concentration 0.4 mg/ml BCA method
Purity .99% Densitometry of silver stained gel
Host cell protein content 4 ng/ml Cygnus host cell ELISA
Host cell protein detection Negative DAKO anti-E. coli western blot
Molecular weight ,35 kDa SDS-PAGE
Molecular weight 32,716 Mass spectrometry
Identity Positive CSP mAb ELISA/Western blot
N-terminal sequence AHHHHHHPGMYGSSSNT Edman sequencing
Sterility Sterile Inoculation method
Stability Stable for 60 hr at 22uC SDS-PAGE
Endotoxin ,6 EU/ml (0.001 EU/mg) LAL Pyrochrome Assay
Pyrogenicity Non-pyrogenic Rabbit pyrogenicity test
doi:10.1371/journal.pone.0111020.t001
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Figure 3. Characterization of CS/D product. A, Purity of CS/D final product analyzed by silver-stained SDS-PAGE. Lanes, 1, 2, 3 and 4 show 2 mg,
1 mg, 0.5 mg, 0.25 mg of CS/D, respectively; M, molecular weight marker. B, Western blot using host cell protein polyclonal antibodies. Lane 1 shows
2 mg CS/D, lane 2 shows 1 mg CS/D; Ec, whole cell E. coli lysate positive control; M, molecular weight marker. C, Size-exclusion HPLC elution profile of
CS/D. D, Mass spectrometry analysis of CS/D. E, Thermal Stability of CS/D shown on a non-reduced SDS-PAGE with temperature and incubation time
shown above the gel. F, Stability of CS/D following a freeze-thaw cycle. Frozen and thawed samples (Thaw) were centrifuged (Spun) were analyzed by
coomassie-stained, reduced (R) and non-reduced (N) SDS-PAGE and by mouse polyclonal anti-CS/D western blot.
doi:10.1371/journal.pone.0111020.g003
Figure 4. ELISA end-point titers of CSP mAbs. Full-length CS/D protein, repeat (NANP)6 peptide and non-reduced or reduced/alkylated (red/alk)
version of a C-term peptide (EPSDKHIKEYLNKIQNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDELDYANDIEKKICKMEKCS) was coated in wells and mAb
dilution that resulted in an OD = 1.0 was plotted.
doi:10.1371/journal.pone.0111020.g004
CSP Based Malaria Vaccine
PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e111020
fermentation, a seed vial was inoculated into 3 L of medium and
grown overnight at 32uC. This overnight culture was inoculated
into 300 L of a medium containing BBL Phytone, (Sparks MD),
yeast extract, ammonium sulfate, potassium and sodium phos-
phate, magnesium sulfate, glycerol, dextrose and kanamycin. The
fermenter was set to 400 RPM agitation, 28uC, 300 L/min air
flow, 3 psig pressure and pH 6.8. The culture was grown to an
OD600 of 7.0 and induced with 0.5 mM IPTG for 2 h. The cell
Figure 5. Immunological responses induced in Balb/c mice by vaccine formulations using SE, Alum or TLR ligands. Groups of 10 Balb/
c mice were immunized with 2 doses of 2.5 mg CSP, 2 months apart in the indicated adjuvant. Two weeks post second immunization, the mice were
bled and the serum was analyzed. A, ELISA end point titers of Balb/c mice, measured against CS/D (left) or NANP repeat peptide (right). B, IgG1 (left)
and IgG2a (right) subclasses measured by Luminex and expressed as mean fluorescence intensities (MFI) at 1:500 serum dilution. C, Percentage of
total cytokine+CD44+CD4+ T lymphocytes, extracted from vaccinated Balb/c mice and stimulated with CS/D, stained for surface expression of CD3,
CD4 and CD44 and intra-cellular expression of IL-2 (left) or IFN-c (right). Lines are mean with SEM. (*) indicates significant P values for ANOVA followed
by Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0111020.g005
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paste was harvested by centrifugation and stored at 280uC. For
purification, the soluble fraction of the cell pellet was extracted in
phosphate buffer by microfluidization, and the resulting lysate was
clarified by centrifugation. CS/D protein was purified over a Ni-
affinity column (Qiagen, Germantown, MD) and eluted using
imidazole. The protein was then passed over a Q Sepharose fast
flow ion-exchange column (GE Healthcare, Waukesha, WI) and
the purified protein was eluted using a combination pH/salt step
gradient. The final product was sterile filtered and stored at 2
80uC.
Product characterization
Antigen purity was assessed by silver staining of SDS-PAGE gels
(GelCode SilverSNAP Kit, Pierce). Host cell proteins were
detected by ELISA using the Cygnus E. coli protein detection
kit (Southport, NC) or by western blot using anti-E. coli antibodies
from Dako (Carpinteria, CA). An analytical size-exclusion
chromatography profile was obtained by loading 25 mg CS/D
on a Shodex KW-803 column connected to a Waters HPLC
system. N-terminal sequencing and mass spectroscopy was
performed by Molecular Structure Facility, University of Cali-
fornia (Davis CA). The endotoxin content of the final product was
measured by the LAL Endotoxin Assay (Associates of Cape Cod,
East Falmouth, MA). Sterility testing was performed by inoculat-
ing the protein bulk into culture media and evaluating for any
bacterial growth. ELISA using CSP-specific monoclonal antibod-
ies was used to establish product identity. In this monoclonal
ELISA, the full-length CS/D protein, a repeat peptide: (NANP)6,
a disulphide-bonded C term peptide: EPSDKHIKEYLN-
KIQNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDEL-
Figure 6. Immunological responses induced in Balb/c mice by CS/D covalently conjugated to 3M-051. Groups on 10 Balb/c mice were
immunized two doses of 2.5 mg CSP, 2 months apart in the indicated adjuvant. One month post second immunization sera were collected and
analyzed. A, ELISA end point titers of mice, measured against CS/D (left) or NANP repeat peptide (right). B, IgG1 (left) and IgG2a (right) subclasses
expressed as Luminex mean fluorescence intensities (MFI) at 1:500 serum dilution. C, Percentage of total Cytokine+CD44+CD4+ T lymphocytes,
extracted from vaccinated Balb/c mice and stimulated with CS/D, stained for intracellular IL-2 (left) or IFN-c (middle) or CD8+ cells stimulated with the
Kd-restricted peptide and stained for IFN-c (right). Lines are mean with SEM.
doi:10.1371/journal.pone.0111020.g006
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DYANDIEKKICKMEKCS (Biomatik USA, Wilmington DE)
and a reduced/alkylated version of this C-term peptide were
coated on the ELISA plate.
Rabbit Pyrogenicity Test
BioReliance (Rockville, MD) performed a rabbit pyrogen test to
detect the presence of pyrogenic substances. Three adult rabbits
(New Zealand white), weighing a minimum of 1.5 Kg received
3 mL/kg of diluted CS/D bulk (0.02 mL bulk +35 mL 0.9%
saline) intravenously through the ear vein. The rectal temperature
was measured at half-hour intervals from one to three hours. CS/
D met the requirements for absence of pyrogens if no rabbit
showed a temperature rise of 0.5uC or greater above its respective
control temperature at any time period during the measurement.
Antigens
A construct containing the C-terminal region of CSP (C-term)
was cloned, expressed and purified to serve as a reagent in ELISA
and Luminex assays. The Biotinlylated peptide NANP-(NANP)5-
NANP-COOH (Luminex assays) and Kd-restricted NYD-
NAGTNL peptide [32] (Balb/c cytokine assays) were synthesized
by Alpha Diagnostics (San Antonio TX). Overlapping 15-mer
Figure 7. Immunological responses induced in C57Bl/6 following 2 vaccinations with CS/D adjuvanted with GLA/SE or 3M051.
Groups on 15 C57Bl/6 mice were immunized with 2 doses of 2.5 mg of CSP, 3 weeks apart, in the indicated adjuvant. Two weeks post second
immunization sera were analyzed. A, ELISA end point titers of mice, measured against CS/D (left) or NANP repeat peptide (right). Two high
responding mice from the 3M051/SE conjugate group were included in statistical analysis but are outside the scale of the NANP graph. B, Relative
IgG1 vs. IgG2c responses against the C term protein (left) or NANP peptide (right) measured by Luminex at 1:2000 serum dilution. C, Percentage of
total Cytokine+CD44+CD4+ T lymphocytes, extracted from vaccinated C57Bl/6 mice and stimulated with CS/D, stained for intracellular IL-2 (left) or IFN-
c (right). Lines are mean with SEM.
doi:10.1371/journal.pone.0111020.g007
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peptides corresponding to the full-length CSP were a gift from Dr.
Martha Sedegah (Infectious Disease Directorate, Naval Medical
Research Center, Silver Spring MD). CSP-specific monoclonal
antibodies (mAbs) were produced in a humanized mouse model
and were selected based on their ability to react to sporozoite CSP
by western blot and by IFA (Dr Ted B. Hall, personal
communication).
Adjuvants and Immunizations
Each vaccine dose contained 2.5 mg of purified CS/D.
Conjugation of CS/D to the imidazoquinoline-derivative 3M-
Figure 8. Immunological responses induced in C57Bl/6 following 3 vaccinations with CS/D adjuvanted with GLA/SE or 3M051.
Groups of 15 C57Bl/6 mice were immunized three times, 3 weeks apart, with 2.5 mg of CSP in the indicated adjuvant. Sera were analyzed 2 weeks
after the last dose. A, ELISA titers of mice measured against CS/D (left) and NANP peptide (right). Two high responding mice from the GLA/SE group
were included in statistical analysis are outside the scale of the NANP graph. B, Relative IgG1 vs. IgG2c responses against the C term protein (left) or
NANP peptide (right) measured by Luminex at 1:2000 serum dilution. C, Percentage of total Cytokine+CD44+CD4+ T lymphocytes, extracted from
vaccinated C57Bl/6 mice and stimulated with CS/D, stained for intracellular IL-2 (left) or IFN-c (right). Lines are mean with SEM.
doi:10.1371/journal.pone.0111020.g008
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051 was performed by 3M Drug Delivery Systems (St. Paul, MN)
using an NHS-Succinimidyl 4-formylbenzoate linker. The final
conjugate vaccine was prepared using a 10 fold molar excess of
3M-051 to CS/D with 70% coupling efficiency. Each 2.5 mg dose
of CS/D-3M051 contained 189 ng of 3M-051. Stable oil in water
emulsion (SE), GLA/SE (0.25 mg/mL), GLA/R848/SE
(0.25 mg/mL GLA+0.05 mg/mL R848), and Alum (1 mg/mL)
were obtained from the Infectious Diseases Research Institute
(IDRI, Seattle, WA). For all SE-based formulations, CS/D in
phosphate-buffered saline (PBS; pH = 7.4) was mixed with the
adjuvant (adjuvant: antigen v/v ratio 1:4), the mixture was
vortexed briefly, and 100 ml was injected subcutaneously (sc) into
the inguinal region of each mouse. For Alum-based formulations,
CS/D was mixed with Alum at a 1:1 ratio (vol/vol), resulting in a
formulation containing 50 mg Alum and 2.5 mg antigen injected sc
into each mouse.
Parasite Challenge and Protection
Protective efficacy was measured using a transgenic (Tr-Pb) spz
challenge model [33,34]. The transgenic P. berghei (Pb) parasite
expresses the full-length P. falciparum CSP [35]. Our initial
immunogenicity studies were carried out in Balb/c mice.
However, it became apparent that C57Bl/6 mice are much more
susceptible than Balb/c mice to infection with the Tr-Pb spz, and
hence all challenge experiments were conducted using the C57Bl/
6 strain. C57Bl/6 mice were given either two or three vaccinations
and challenged intravenously (iv) with approximately 3000 spz two
weeks after the final immunization, as described by Porter et al.
[33]. Protection was defined as the absence of blood stage infection
14 days post-challenge as observed via oil immersion microscopy
of a Giemsa stained thin smear.
Reagents
CSP specific monoclonal antibodies used to characterize
recombinant CSP were generated in mice against a full-length
CSP recombinant protein [36] and showed positive reactivity to Pf
sporozoites by IFA and western blot (Dr. Ted B. Hall, personal
communication). PE-anti-mouse IgG, PE-anti-mouse IgG1, PE-
anti-mouse IgG2c and PE-anti-mouse IgG2a were obtained from
Jackson Immunoresearch (West Grove, PA). Luminex beads and
Luminex Streptavidin beads were purchased from Luminex
Corporation (Austin, TX) and 96-well Luminex Multi-screen BV
Table 2. C57Bl/6 mouse protection data following two or three immunizations with CS/D combined with multiple adjuvants.
Adjuvant CS/D Protection
mg 2-dose 3-dose
3M051 2.5 4/10 4/10
GLA/SE 2.5 2/10 6/10
SE 2.5 1/10 2/10
SE 0 0/10 N/A








Figure 9. Protective efficacy in C57Bl/6 mice against transgenic P. berghei sporozoite challenge. A, Survival curves of C56Bl/6 mice
(n = 10), challenged with the transgenic parasites in the 2-dose (left) or 3-dose (right) study. Protection was defined as the absence of blood stage
infection until day 14 post challenge.
doi:10.1371/journal.pone.0111020.g009
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1.2 micron assay plates were acquired from Millipore Corporation
(Billerica, MA). Antigens were coupled to the Luminex beads
according to the manufacturer’s instructions. PerCP anti-CD3
(clone 145-2C11), Pacific Blue anti-CD4 (clone RM4-5), Horizon
V500 anti-CD8 (clone 53-6.7), Alexa 700 anti-CD44 (clone IM7),
FITC anti-IL-2 (clone JES6-5H4), APC anti-IFN-c (clone
XMG1.2), anti-CD16/CD32 FcR Block (clone 2.4G2), anti-
CD28 (clone 37.51), anti-CD49d [clone 9C10(MFR4.B)], Cyto-
fix/Cytoperm and Golgi Plug were all obtained from BD
Biosciences (San Jose, CA). LIVE/DEAD Fixable Blue Dead Cell
Stain Kit for UV excitation was purchased from Invitrogen
(Camarillo, CA). Phorbol 12-myristate 13 acetate (PMA) and
Ionomycin were obtained from Sigma Chemicals (St. Louis, MO).
ELISA
Immulon 2HB plates (Thermo Scientific, Rochester, NY) were
coated overnight at 4uC with either 50 ng/well recombinant CS/
D or 20 ng/well (NANP)6 peptide. Plates were washed with PBS
containing 0.05% Tween-20 (PBS/T) and blocked with PBS
containing 1% casein for 1 h. 100 ml of serially diluted primary
antibody was added to the wells in duplicate for 2 h at 22uC, the
plates were washed 3x with PBS/T, and 50 ml of a 1:15,000
dilution of HRP-conjugated, anti-mouse IgG (Southern Biotech,
Birmingham, AL) was added per well. After a 1 h incubation, the
plates were washed 4x with PBS/T and developed using 50 ml/
well ABTS peroxidase substrate system (KPL, Gaithersburg, MD)
for 1 h. OD415 was measured using a Biotek Synergy 4 microplate
reader (Highland Park, VT), and endpoint titer, defined as the
serum dilution that resulted in an OD415 of 1.0, was calculated
using Gen5 software (Biotek). For the monoclonal ELISA, serial
dilution of humanized-mouse monoclonal antibodies against CSP
(starting at 1:500 dilution of 1 mg/ml mAb) were added to the
wells and the ELISA was developed as described above using
human secondary antibody.
Avidity ELISA
The avidity ELISA protocol was similar to that described above,
except an additional wash step was added involving incubation
with either 6 M Urea or PBS for 10 min following the primary
antibody binding step. Avidity index was defined as the percentage
of antibody that remained bound to antigen after the urea
wash = (endpoint titer with urea wash)/(endpoint titer with PBS
wash)6100.
Luminex
To determine serum dilutions for the Luminex analysis
(Luminex Corporation, Austin, TX), serum from several repre-
sentative high and low responder mice were first analyzed. These
sera were serially diluted and MFI response measured by
Luminex. Titration curves were drawn and a dilution that fell
on the linear part of the curve for most samples was chosen. A
representative titration experiment is shown in Figure S1.
Subsequently, all serum samples were run at this one selected
dilution. Mouse serum was collected at 1 month (Balb/c) or 2
weeks (C57Bl/6) after the final immunization and diluted to 1/500
(Balb/c) or 1/2000 (C57Bl/6) in PBS containing 1% BSA (assay
buffer). 50 ml of the serum plus assay buffer mixture was added to
the wells of a Luminex plate followed by 50 ml of assay buffer
containing 3000 CS/D-coupled beads or 3000 beads coupled with
C-term protein plus 3000 beads (with a different bead signature)
coupled to NANP. The plates were agitated on a shaker for 1 h at
room temperature and washed in assay buffer containing 0.05%
Tween-20. 100 ml of assay buffer containing PE-labeled-(mouse
IgG subclass)-specific antibody was then added to the wells and the
plate was agitated for an additional hour. The plate was washed
and mean fluorescence intensity (MFI) was measured using a
Luminex 200 system (Luminex Corporation, Austin, TX).
Cytokine Production Assay
To allow for the development of stable memory cells, spleens
were obtained from either Balb/C or C57Bl/6 mice at least six
weeks after the final immunization. Spleen cells (106 per well) were
cultured with anti-CD28 (1 mg/ml) and anti-CD49d (1 mg/ml) co-
stimulants plus either medium (negative control), CS/D protein
(10 mg/ml), Kd-restricted CD8 T cell peptide (10 mg/ml) or a pool
of overlapping 15-mer peptides covering the entire CSP sequence
(2 mg/ml). Naı¨ve T cells cultured with CS/D served as an
additional negative control, and PMA/Ionomycin was used as the
positive control. Cells were incubated for 2 h at 37uC in a 96-well
round-bottom culture plate and Golgi plug was added for an
additional 4 h at 37uC. Cells were stored at 4uC overnight and
then transferred to a 96-well, V-bottom plate for surface-staining
of CD3, CD4, CD8, and CD44. Subsequently, cells were washed
Figure 10. Dose response study of CS/D+GLA/SE vaccine in C57Bl/6 mice. Groups of 7 mice received three immunizations of 0.1, 1, 2.5, 5 or
10 mg CS/D, adjuvanted with GLA/SE at two week intervals. ELISA end-point titers were measured 2 weeks after the last dose against CS/D (left) or
NANP (right). Red circles represent protected mice while black circles represent non-protected mice.
doi:10.1371/journal.pone.0111020.g010
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and fixed/permeabilized simultaneously with Cytofix/Cytoperm.
Cells were stained for intra-cellular IFN-c and IL-2, washed, and a
minimum of 300,000 cells per sample were acquired on an LSR II
multicolor flow cytometer (BD Biosciences). A typical gating
scheme for the detection of cytokine producing CD4+ and CD8+ T
cells is shown in Figure S2. Viable lymphocytes were gated for
CD3+ cells and further gated to reveal CD4+ and CD8+ T cells.
The CD4+ population was differentiated by the presence of CD44
to reveal activated CD4+ T cells producing cytokines. Data was
analyzed using FlowJo software (Tree Star, Ashland, OR).
CD86 expression assay
Splenic lymphocytes from naı¨ve mice were incubated overnight
with medium alone (negative control), 1 mg/ml of CS/D, 1 mg/ml
CS/D-3M051, or 1 mg/ml TLR ligand-containing adjuvants. The
cells were washed and stained for surface expression of CD3,
CD19, and CD86 and flow cytometry data was acquired as above.
Viable lymphocytes were gated to reveal CD19+ B Cells. Data was
analyzed using FlowJo software.
Statistics
ELISA and Luminex data were log transformed and two-way
comparisons were made by unpaired t-test on the GraphPad Prism
software (La Jolla, CA). Multiple comparisons were made by
ANOVA and p-values were corrected using Tukey’s method.
Statistically significant difference in group means was indicated in
figures as **** (p,0.0001), *** (p,0.001), ** (p,0.01), or * (p,
0.05). Parasite challenge data on day 14 were analyzed by the
Fisher’ exact test. Survival curves were compared using log rank
test and Dunnett’s method was used to adjust p values for multiple
comparisons (SAS software version 9.3).
Results
Expression and characterization of CS/D in Escherichia
coli
P. falciparum 3D7 strain CSP is composed of the N-terminal
region which harbors one cysteine residue, followed by 4 NVDP
and 38 NANP repeats and a C terminal region that harbors four
additional cysteines that form two disulphide bonds (Fig. 2A) [37].
At the time of hepatocyte invasion, the N-terminal region of CSP
is proteolytically processed [38], but the exact processing site has
not been mapped. Our expression constructs were designed to
include a majority of the N-terminal region of PfCSP. The
construct CS/A (Fig. 2A) that contained all 5 cysteines, resulted in
a protein that aggregated at low concentrations and was not stable
during freeze-thaw cycles. All subsequent constructs were
therefore designed to exclude the first cysteine, initiating
expression at Tyr26 (Fig. 2A). In order to optimize the number
of repeats in the antigen, we produced three proteins: CS/C
(2NVDP+5NANP repeats), CS/D (3NVDP+19NANP) and CS/E
(4NVDP+38 NANP) (Fig. 2A). CS/E contained all PfCSP repeats
but it expressed at ,3% of total cell protein, in contrast, CS/C
and CS/D (which contained fewer repeats) expressed at ,14% of
total cell protein (Fig. 2B). In a mouse immunogenicity study, the
CS/C protein produced very low level NANP-specific antibodies
and failed to induce protection against transgenic P. berghei
challenge [33] and hence the process development efforts were
focused on the CS/D construct. CS/D protein partially
partitioned into the soluble fraction of E. coli and the soluble
protein was extracted and purified using a 2-step process.
Product characterization
A summary of the results of various tests performed on the final
product is shown in Table 1. The final product contained .99%
pure CS/D protein, as determined by silver-staining of SDS-
PAGE gels (Fig. 3A). No E. coli-specific bands were detected by
western blot using host cell protein antibodies (Fig. 3B), and using
a more sensitive host cell-protein ELISA revealed that 400 mg/ml
bulk protein contained 4 ng/ml bacterial proteins. On an
analytical size-exclusion column, CS/D eluted as a single peak,
confirming the conformational homogeneity of the product
(Fig. 3C). N-terminal sequence of CS/D protein was
AHHHHHHPGMYGSSSNT, confirming the processing of the
terminal methionine, the presence of a 6xHis tag and 7 CSP
specific residues (Table 1, in bold). Mass spectrometry analysis
showed one peak at 32,715.9 Da which is close to the predicted
mass of 32,717.9 Da (Fig. 3D). The endotoxin content of CS/D
was 6 EU/ml (0.015 EU/mg protein) as measured by the
Pyrochrome LAL kit and the product was non-pyrogenic in
rabbits. The final product was sterile filtered and it passed the
sterility test. The protein was stable at temperatures below 22uC
for up to 96 h. Aggregation was noticeable after 60 h incubation
at 37uC and some degradation was observed after 96 h at 37uC
(Fig. 3E). No loss of product due to precipitation was observed
when CS/D samples were frozen, thawed and analyzed by SDS-
PAGE/western blot, before or after centrifugation (Fig. 3F).
The immunological identity of CS/D was established by ELISA
against a panel of CSP-specific monoclonal antibodies (mAbs)
(Fig. 4). MAbs 3A7, 10A8, 10A9 and 13F3 bound to the NANP
repeat region. Mabs 4D6 and 5G10 bound to a conformation-
dependent epitope represented by a disulphide-bonded C-term
peptide. Significantly lower mAb reactivity was observed when this
C-term peptide was reduced/alkylated to break the disulphide
bonds using DTT/iodoacetamide. Three mAbs 7C18, 8A6 and
12C6 recognized epitopes present only within the full-length CS/
D. The final CS/D product showed high level reactivity to all of
the above CSP-specific mAbs (Fig. 4).
Effects of TLR agonists on immunogenicity of CS/D in
Balb/c mice
We have previously reported that CS/D adjuvanted with
Montanide ISA720 at a 2.5 mg dose gave low level protection (20–
30%) in the transgenic parasite challenge model [33]. Hence,
immunizations in the current study were conducted at the sub-
saturating, 2.5 mg dose of GMP CS/D. In the first experiment, a
group of 10 Balb/c mice received two immunizations of CS/D, at
two month intervals, using four different adjuvants: SE, Alum,
GLA/R848/SE, GLA/SE. The adjuvant control group received
PBS+GLA/R848/SE. The full-length, CS/D-specific ELISA
titers of the GLA/SE and GLA/R848/SE groups did not differ
but both were higher than the Alum group (Fig. 5A). The central
NANP repeat titers were not different between vaccine groups.
Subclass analysis revealed that the TLR agonist-containing groups
GLA/SE and GLA/R848/SE induced 3-fold higher IgG2a and
Figure 11. Comparison of serological profiles of protected and non-protected C57Bl/6 mice. Antibody data from the two C57Bl/6 mice
challenge studies were combined and plotted separately for protected (P) mice and non-protected (NP) mice. A, NANP titers (left) or CS/D titers
(right). B, IgG1 (upper panels) or IgG2c (bottom panels) subclass responses expressed as Luminex MFI, measured against the C term protein (left
panels) or NANP repeat peptide (right panels). The p values are for two-way T-tests on log transformed data.
doi:10.1371/journal.pone.0111020.g011
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lower 1gG1 than SE (Fig. 5B). To assess T cell responses, CS/D-
specific IL-2+ and IFN-c + cells were measured as a percentage of
total CS/D-specific CD44+ CD4+ T cells. GLA/R848/SE
induced higher T cell responses than the adjuvant control and
the Alum group (Fig. 5C). No IL-2 or IFN-c-producing CD8+ T
cells were detected in this immunization study.
The CS/D ELISA titers of the alum group were lower than
those induced by SE (Fig. 5A) and the subclass pattern and T cell
responses induced by Alum were similar to SE (Fig. 5B, C).
Therefore, alum formulations of CS/D were not included in any
subsequent immunogenicity studies. Overall, the addition of the
TLR agonist GLA to the SE formulation was found to augment
CS/D-specific antibody production, IgG2a levels and a trend
towards enhanced CS/D-specific T-cell responses. Vaccination
with the GLA/R848/SE formulation resulted in a larger spread in
the levels of cytokine-producing CD4+ T cells as compared to
GLA/SE, but no overall improvement in immunogenicity was
observed when the unconjugated TLR7/8 ligand R848 was added
to GLA/SE (Fig. 5).
Immunogenicity of CS/D covalently conjugated to a
TLR7/8 agonist
In order to determine whether the adjuvant activity of TLR7/8
agonists would improve as a result of co-internalization with CS/
D, we tested the immunogenicity of a covalently conjugated
TLR7/8 ligand 3M051. The 3M051 conjugate was formulated
with either SE or GLA/SE and its immunogenicity was compared
to CS/D formulated in GLA/SE. The CS/D- and NANP-specific
IgG antibody responses of the two 3M051 groups were similar to
the GLA/SE (Fig. 6A). At the subclass level, 3M051, either in SE
or combined with GLA/SE, induced higher IgG2a and lower
IgG1 than GLA/SE (Fig. 6B). Although the T cell analysis was
limited by low numbers of mice in each group there was also a
trend towards higher IFN-c + CD4+ T cell responses in the 3M051
groups as compared to GLA/SE (Fig. 6C). Additionally, a weak
IFN-c+ CD8+ T cell response was noted in all vaccine groups
(Fig. 6C). Conjugation of CS/D to 3M051 promoted a greater
TH1 bias than GLA/SE. However, the overall immunogenicity of
the 3M051 conjugate was similar to GLA/SE and no improve-
ment was observed when the two were combined, and hence
mixtures of TLR agonists were not evaluated further.
Effect of TLR agonists on CS/D immunogenicity in C57Bl/
6 mice
The 3M051-induced shift towards IgG2 and a trend towards
higher IFN-c T cell responses in Balb/c mice prompted us to
compare the efficacy of this 3M051 conjugate to the efficacy of
CS/D formulated in GLA/SE against a transgenic parasite
challenge. As described in the methods section, Balb/c mice were
somewhat resistant to infection with transgenic parasites, and
hence the challenge experiments were carried out in the more
susceptible C57Bl/6 strain. This set of experiments also allowed us
to investigate the immune responses in an alternative genetic
background with different TH1/TH2 predispositions. Two immu-
nizations with 2.5 mg CS/D formulated with SE or GLA/SE or
conjugated to 3M051/SE were given to groups of 15 mice at a one
month interval. Two weeks after the second immunization, the
ELISA titers against CS/D were similar between groups, but the
NANP repeat titers induced by the TLR-containing formulations
3M051/SE and GLA/SE were significantly higher than those of
SE (Fig. 7A). When IgG subclass analysis was dissected into
NANP and C-term responses, each of the three adjuvants showed
a unique IgG2 vs. IgG1 profile. 3M051/SE induced high IgG2c
levels and almost no IgG1, whereas the SE formulation showed
the opposite subclass distribution (low IgG2 and high IgG1) to
both C term and NANP. In contrast, GLA/SE induced similar
levels of IgG2 and IgG1 antibodies (Fig. 7B). Overall, the 3M051
conjugate induced significantly lower levels of IgG1 as compared
to SE or GLA/SE-adjuvanted CS/D. Spleens from 5 of the 15
immunized mice were harvested for T cell analysis. The IL-2 and
IFN-c CD44+ CD4+ T cell responses of the GLA/SE group were
higher than SE, while T cell responses in the 3M051/SE group
were not statistically different from SE (Fig. 7C).
In another study three immunizations with 2.5 mg CS/D
formulated with SE or GLA/SE or conjugated to 3M051/SE were
given to groups of 15 mice at 3 week interval. Unlike the two dose
study, higher ELISA titers against CS/D were induced by GLA/
SE as compared to 3M051/SE (Fig. 8A). The 3M051 conjugate
again induced lower levels of IgG1 than SE or GLA/SE-
adjuvanted CS/D, but the unique IgG2 vs. IgG1 profile of
3M051/SE observed in the two dose study (high IgG2c and almost
no IgG1) was evident only for the C-term responses (Fig. 8B). A
balanced TH1/TH2 response characterized by similarly high levels
of IgG2 and IgG1 antibodies against C-term and NANP was once
again confirmed for the GLA/SE group (Fig. 8B). T cell analysis
performed on 5 of the 15 immunized mice also confirmed that
GLA/SE was a more potent adjuvant than SE and 3M051/SE
(Fig. 8C). Antibody avidity against CS/D- or NANP was
measured but it showed no difference between groups (data not
shown).
Effect of TLR agonists on protective efficacy against Tr-Pb
sporozoite challenge
The remaining 10 C57Bl/6 mice from the two immunization
experiments were challenged intravenously with 3000 transgenic
sporozoites two weeks after the final immunization. In the two
dose study, all the mice in the adjuvant control group (PBS+SE)
developed patent blood-stage malaria by five days post-infection.
In contrast, 4/10 mice in the 3M051/SE group, 2/10 mice in the
GLA/SE group and 1/10 mice in the SE group remained sterilely
protected at 14 days post-challenge (Table 2). The log rank test
was used to compare survival time of mice between experimental
groups and Dunnett’s method was used to adjust P values for
multiple comparisons. There was a significant difference in
survival time between experimental groups for the 2 dose study
(Chi-square = 28.11, DF = 3, P,0.0001). More specifically, the
survival time for the control group was less than CSP adjuvanted
with GLA (adjusted P = 0.0060), 3M051/SE (P,0.0001), and SE
(P = 0.0360) (Fig. 9).
In the three-dose study, all naı¨ve controls developed blood-stage
malaria by day six post-infection but 4/10 mice in the 3M051/SE
group, 6/10 mice in the GLA/SE group and 2/10 mice in the SE
group remained sterilely protected on day 14 post challenge
(Table 2). As in the first challenge study a significant difference in
survival time between experimental groups was observed (Chi-
square = 18.11, DF = 3, P = 0.0004) and survival time for the
control group was less for CSP adjuvanted with GLA (P = 0.0004)
and 3M051 (P = 0.0130) (Fig. 9). In both studies, the protective
efficacy at the end of the trial for CSP adjuvanted with GLA/SE
and 3M051/SE were not statistically significant (Fischer’s exact
test). The difference in protection, 2/10 and 6/10 in the GLA/SE
group of the 2-dose and 3-dose studies respectively was reflected in
the higher CS/D titers (,15000 vs. ,25000) (Fig. 7A and 8A).
Based on the above data, the GLA/SE formulation was selected
for further evaluation in the challenge model. Three doses of 0.1,
1, 2.5, 5, or 10 mg of CS/D formulated in GLA/SE were
administered to 7 C57Bl/6 mice at 2 week interval. Two weeks
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after the third immunization, ELISA titers generally increased
with escalating antigen dose (Fig. 10). The CS/D and NANP titers
at 0.1 mg was significantly lower than all higher dose groups.
However increase in titer from 1 to 10 mg was less pronounced,
except that the NANP titer of 1 mg group was lower than the
10 mg group. Two weeks after the third immunization, mice were
challenged with Tr-Pb sporozoites. All 7 mice in the PBS+GLA/
SE adjuvant control group were positive by day six and only 1/7
mice in the 0.1 mg dose group was protected on day fourteen. As
predicted by ELISA titers, higher protection was observed for the
1 mg (4/7 protected), 2.5 mg (6/7 protected), 5 mg (5/7) and 10 mg
(6/7) dose groups (Fischer’s exact test p values comparing 0.1 mg
against 1, 2.5, 5 and 10 mg groups were 0.2, 0.007, 0.03 and 0.007
respectively) (Table 2). The above data confirmed that GLA/SE-
adjuvanted CS/D could induce potent antibody responses and
protection against transgenic parasite challenge in mice.
IgG2 associates with protection
To study the role of antibodies in mediating protection, ELISA
and subclass data of the challenged C57Bl/6 mice were plotted
separately for protected and non-protected mice (Fig. 11).
Protected mice had significantly higher total CS/D and NANP-
specific IgG responses as compared to non-protected mice
(Fig. 11A). When antibody subclasses were further dissected,
protection was significantly associated with high levels of IgG2c
against NANP and C term while IgG1 antibody levels failed to
distinguish the protected and non-protected groups (Fig. 11B). No
difference in the avidity of protected and non-protected mice was
observed (not shown).
TLR agonists increase CD86 production on B cells
Both T and B cell activation is controlled by a series of co-
stimulatory molecules. Prominent among these is CD86, a central
co-stimulatory molecule that augments the activation of T cells
and is up-regulated by cytokines. As a preliminary exploration of a
mechanism underlying GLA and R848 amplification of humoral
and cell-mediated immunity, the effects of the TLR4 and TLR7/8
agonists on the expression of CD86 on B cells were investigated.
In vitro exposure of murine spleen cells to the adjuvants GLA/SE
or GLA/R848/SE produced a marked increase in expression of
the co-stimulatory CD86 molecule on CD19+ B cells (Figure S3).
A similar increase in CD86 was observed in the presence of the
CS/D-3M051 while CS/D in the absence of the conjugated
3M051 had no measurable effect on CD86 levels (Figure S3).
Discussion
The native P. falciparum CSP gene codes for an N-terminal
segment which is followed by 4 NVDP repeats, 38 NANP repeats,
and a C-terminal cysteine rich region (Fig. 2A). Although the
central repeat and C-terminal regions contain the primary B and
T cell epitopes [39], several T helper and CTL epitopes have been
mapped to the N-terminal region [32,40,41]. The N-terminal also
plays a key role in the process of sporozoite invasion and inclusion
of the N-terminal region could be a way to improve the efficacy of
CSP based vaccines [42] [38]. High level expression of a nearly
full-length CSP in E. coli has however remained a major hurdle.
Of the 3 reports on full-length P. falciparum CSP expression, the
first recounted that the full-length CSP gene cannot be expressed
in E. coli [43] and the two subsequent reports showed expression
of an insoluble protein that required extensive refolding to gain
solubility [36,44]. We demonstrate that a nearly full-length PfCSP
construct can be expressed and purified from the soluble fraction
of E. coli. The final GMP product met the purity, homogeneity
and stability criteria for clinical use products and it reacted to both
conformational and non-conformational CSP specific monoclonal
antibodies (Fig. 4 and Table 1). A comparative immunogenicity
study was next conducted to find a suitable adjuvant for the
soluble cGMP grade CS/D antigen.
Given the safety and regulatory concerns for vaccines primarily
targeted for use in children, any combination of novel adjuvants
would need to demonstrate significant enhancement of CSP-
specific immunity for serious consideration towards advanced
development. We tested TLR4 agonist containing adjuvants
GLA/SE and two TLR7/8 agonists containing adjuvants R848
(soluble) and 3M051 (conjugated). The 3M051 adjuvant offered no
improvement over GLA/SE in the C57Bl/6 protection model.
Additionally, the 3M051 formulation would require another GMP
conjugation, increasing manufacturing costs for a vaccine targeted
at low resource countries. Hence, our study data favors the use of
GLA/SE over 3M051/SE as an adjuvant for soluble CS/D.
Contrary to the TLR synergy hypothesis, adding R848 and
3M051 to GLA/SE showed no improvement in antibody
responses or subclass profile, relative to 3M051/SE or GLA/SE
administered individually. This lack of synergy could be because
the dose of the two adjuvants was relatively high. Moreover, TLR4
signals through both the TRIF and MyD88 pathways [12,45] and
synergistic combinations of GLA with the TRIF pathway ligand
Poly(I-C) may be worth exploring with CSP vaccines [46].
Kastenmuller et al. compared poly-ICLC (a TLR3 agonist) to
GLA/SE for its capacity to induce an immune response to nearly
full-length CS proteins in the rodent model. In that study, poly-
ICLC was found to induce higher T-cell responses than GLA/SE,
although no differences in antibody responses were reported [46].
If antibodies are a prime mediator of CSP-based protection, as was
determined in past RTS,S vaccine studies [5], GLA/SE is likely to
be at least as effective as poly-ICLC. We showed that the GLA/SE
formulations of CS/D induced a robust antibody response,
measureable T-cell responses and 86% protection in mice that
received three doses of 2.5 mg E. coli-produced CS/D (Table 2).
While only a head-to-head comparison of vaccine formulations
can be definitive, it is notable that three doses of the poly-ICLC
formulation containing 20 mg of a similar E. coli produced CSP
showed about 50% sterile protection against a CSP repeat
transgenic P. berghei parasite [46].
In our attempts to study the capacity of adjuvants to promote
immune responses to our CS/D vaccine, it became evident that
magnitude of total IgG as measured by ELISA was not sufficient to
reveal the essential features of the antibody response. Although our
experimental design did not allow us to dissect the role of cellular
immunity, we show for the first time that CS/D-specific IgG2c
levels were significantly higher in protected C57Bl/6 mice as
compared to non-protected mice while IgG1 titers did not appear
to associate with protection. Although the CS/D-vaccinated Balb/
c mice were not challenged, GLA/SE and GLA/R848/SE also
stimulated much stronger IgG2a, but weaker IgG1 responses than
SE in this mouse strain.
A trend towards increased protection from re-infection with
malaria has been noted in individuals who possess higher levels of
cytophilic, CSP-specific antibodies in the field [47]. In mice, the
IgG2 subclass is cytophilic, as it can fix complement [48] and
opsonize pathogens for phagocytosis more effectively than IgG1
[49]. In humans, it is the IgG1 and IgG3 subclasses that are
cytophilic, while IgG2 and IgG4 have been shown to inhibit
cytophilic activity [50]. This study did not find a negative
correlation between IgG1 responses and protection in the mouse
model and unlike 3M051, GLA/SE was found to promote high
levels of both IgG2 and IgG1, in two strains of mice. The overall
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results suggest that that our E. coli-derived CS/D adjuvanted with
GLA/SE merits further evaluation in the rhesus monkey model
and subsequently in humans.
Supporting Information
Figure S1 Representative titration curve for Luminex
dilution determination. Figure shows titration of representa-
tive high and low responder mice in the GLA/SE and SE groups
from the 3 vaccination C57Bl/6 challenge experiment. The dotted
black line was drawn at the 1:2000 dilution, selected for further
analysis on all sera.
(TIF)
Figure S2 Gating scheme for intra-cellular staining of T
cells from Balb/c mice. Mice were vaccinated with 2 doses of
a CS/D-3M051 formulation and 6 weeks after the final
vaccination splenic lymphocytes were extracted and stimulated
with CS/D or the CS protein Kd-restricted peptide (CD8). A,
Total cell population (.= 300,000 cells/sample) was gated for
viable cells, CD3 T cells and CD4 or CD8 T cells. B,
Representative dot plots showing the expression of IFN-c in
CD44+CD4+ naı¨ve cells cultured with CS/D, immune cells
cultured in culture medium only (CM) or immune cells cultured
with CS/D. C, Representative dot plots showing the expression of
IFN-c in CD8+ naı¨ve cells cultured with CS/D, immune cells
cultured in culture medium only or.
(TIF)
Figure S3 Adjuvant-mediated up-regulation of CD86 in
C57Bl/6 mice. Left, CD86 expression on CD19+ B cells from
naı¨ve C57Bl/6 mice were incubated overnight (see methods) with
medium alone (red), 1 mg/ml GLA/SE (blue) or 1 mg/ml of
GLA/R848/SE (green). Right, medium alone (red), 1 mg/ml CS/
D (blue) or 1 mg/ml CS/D-3M051 conjugate (green).
(TIF)
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